Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuo Momma

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Cancer Medicine|March 27, 2018
Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancerShuichi Nishimura, Toshio Ohashi, Tetsuo Momma, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 31, 2015
Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapyShinya Sutani, Toshio Ohashi, Masanori Sakayori, et al.
Medical Oncology (Northwood, London, England)|October 25, 2017
Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapyKyohei Hakozaki, Eiji Kikuchi, Keishiro Fukumoto, et al.
Japanese Journal of Clinical Oncology|May 8, 2019
Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapyGo Kaneko, Suguru Shirotake, Koshiro Nishimoto, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)Atsunori Yorozu, Mikio Namiki, Shiro Saito, et al.
European Urology Focus|July 21, 2017
External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional StudyNobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, et al.
Urologic Oncology|November 10, 2016
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk modelNobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, et al.
Japanese Journal of Clinical Oncology|November 9, 2018
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinomaKeiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, et al.
Clinical Genitourinary Cancer|April 23, 2016
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell CarcinomaSuguru Shirotake, Yota Yasumizu, Keiichi Ito, et al.
Urologic Oncology|April 5, 2016
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settingsNobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Cancer Medicine|March 27, 2018
Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancerShuichi Nishimura, Toshio Ohashi, Tetsuo Momma, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 31, 2015
Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapyShinya Sutani, Toshio Ohashi, Masanori Sakayori, et al.
Medical Oncology (Northwood, London, England)|October 25, 2017
Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapyKyohei Hakozaki, Eiji Kikuchi, Keishiro Fukumoto, et al.
Japanese Journal of Clinical Oncology|May 8, 2019
Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapyGo Kaneko, Suguru Shirotake, Koshiro Nishimoto, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)Atsunori Yorozu, Mikio Namiki, Shiro Saito, et al.
European Urology Focus|July 21, 2017
External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional StudyNobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, et al.
Urologic Oncology|November 10, 2016
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk modelNobuyuki Tanaka, Ryuichi Mizuno, Yota Yasumizu, et al.
Japanese Journal of Clinical Oncology|November 9, 2018
Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinomaKeiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, et al.
Clinical Genitourinary Cancer|April 23, 2016
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell CarcinomaSuguru Shirotake, Yota Yasumizu, Keiichi Ito, et al.
Urologic Oncology|April 5, 2016
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settingsNobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, et al.
Pageof 4